A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: A north central cancer treatment study, N0021

Cancer

Volumn 112, Issue 8, 2008, Pages 1772-1779

  Okuno, Scott H ^a   Delaune, Robert ^b   Sloan, Jeff A ^a   Foster, Nathan R ^a   Maurer, Matthew J ^a   Aubry, Marie Christine ^a   Rowland Jr , Kendrith M ^c   Soori, Gamini S ^d   Nikcevich, Daniel A ^e   Kardinal, Carl G ^f   Northfelt, Donald W ^g   Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

^b Metro Minnesota Community Clinical Oncology Program   (United States)

^c Carle Cancer Center CCOP   (United States)

^d MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^e Duluth CCOP   (United States)

^f Ochsner CCOP   (United States)

^g Ochsner CCOP ^*  (United States)

Author keywords

Chemotherapy; Epirubicin; Gemcitabine; Pleural mesothelioma

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFUSION; CONSCIOUSNESS DISORDER; CONSTIPATION; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEART ARREST; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPOXIA; INFARCTION; INFECTION; ISCHEMIA; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; PERSONALITY DISORDER; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PLEURAL PAIN; PLEURISY; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RECTUM FISTULA; SIDE EFFECT; STOMATITIS; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; LEUKOPENIA; MALE; MESOTHELIOMA; MIDDLE AGED; NEUTROPENIA; PLEURAL NEOPLASMS; QUALITY OF LIFE; REMISSION INDUCTION; RIBONUCLEOTIDE REDUCTASES; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 42149095965     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23313     Document Type: Article

References (27)

1. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic [see comment]. Br J Cancer. 1999;79:666-672.
2. Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer. 2005:92:587-593.
3. Maziak DE, Gagliardi A, Haynes AE, et al. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer. 2005;48:157-169.
4. Sugarbaker DJ, Heher EC, Lee TH, et al. Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma [see comment]. J Thorac Cardiovasc Surg. 1991;102:10-14; discussion 14-15.
5. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54-63; discussion 63-65.
6. Pass HI, Temeck BK, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol. 1997;4:628-633.
7. Pass HI, Kranda K, Temeck BK, et al. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol. 1997;4:215-222.
8. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study [see comment]. J Clin Oncol. 1999;17:25-30.
9. Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87:491-496.
10. van Haarst JM, Baas P, Manegold Ch, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002;86:342-345.
11. Magri MD, Veronesi A, Foladore S, et al. Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)-Mesothelioma Committee. Tumori. 1991;77:49-51.
12. Berghmans T, Lafitte JJ, Paesmans M, et al. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Lung Cancer. 2005;50:75-82.
13. Kreil A, Bauer J, Scheithauer W. In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma [in German]. Acta Medica Austriaca. 1999;26:93-100.
14. Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of 4 tools measuring overall quality of life in patients with advanced cancer [see comment]. J Clin Oncol. 1998;16:3662-3673.
15. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chron Dis. 1981;34:585-597.
16. Holmes S. Use of a modified symptom distress scale in assessment of the cancer patient. Int J Nurs Stud. 1989;26:69-79.
17. Therasse P, Arbuck SJ, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [see comment]. J Natl Cancer Inst. 2000;92:205-216.
18. National Cancer Institute. NCI Common Toxicity Criteria. Available at: http://ctep.cancer.gov Accessed January 1, 2008.
19. Sargent DJ, Chan V, Goldberg RM. A 3-outcome design for phase II clinical trials. Control Clin Trials. 2001;22:117-125.
20. Duffy DE, Santner TJ. Confidence intervals for a binomial parameter based on multistage tests. Biometrics. 1987;43:81-93.
21. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
22. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika. 1965;52:591-610.
23. Baas P. Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Semin Oncol. 2002;29:62-69.
24. Luftner D, Flath B, Akrivakas C, et al. Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study. Invest New Drugs. 1998;16:141-146.
25. van Putten JW, Eppinga P, Erjavec Z, et al. Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study. Br J Cancer. 2000;82:806-811.
26. Tsavaris N, Mylonakis N, Karvounis N, et al. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma [see comment]. Lung Cancer. 1994;11:299-303.
27. Fennell DA, C Steele JP, Shamash J, et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer. 2005;47:277-281.